This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

In an era where chronic diseases are reshaping global health priorities, the diabetic retinopathy market stands out as a ...

MUSCAT: The National Programme for Early Detection of Diabetic Retinopathy using artificial intelligence (AI) technologies ...

Two studies were conducted to verify concerns about diabetic retinopathy that were raised during initial trials of ...

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a ...

Eye floaters, those drifting spots in your vision, are often harmless but can signal hypertension or diabetes. High blood ...

An Editorial in The Lancet Neurology emphasised that rigorous prospective studies are essential to develop safe and ethical artificial intelligence (AI) tools for brain health.1 Yet, what usually ...

New studies found that Americans with type 2 diabetes who are taking GLP-1 drugs like Ozempic and Mounjaro could face an ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Two new JAMA Network Open studies link popular diabetes and weight loss drugs, including Ozempic and Mounjaro, to a slightly ...

PROGRESS HAS stalled on the development of a €4 million HSE national screening programme to identify the sight-threatening condition diabetic retinopathy (DR). One person with diabetes goes ...